Current and Future Treatment Strategies for Acute Myeloid Leukemia

Gain insight on the latest investigative treatments for AML, including targeted therapies for FLT3- and IDH1/2-positive AML and combination strategies.
Naval G. Daver, MD

ClinicalThought

Gain insight on the latest investigative treatments for patients with FLT3-positive AML with this expert commentary.

Naval G. Daver, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 31, 2020 Expired: July 30, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue